EGFR and adenocarcinoma: Activation of the EGFR pathway mediated by activating mutations in its constituents is a key driver in adenocarcinomas of the lung, mediating important carcinogenic properties such as cell-cycle progression, apoptosis, angiogenesis and metastasis [5].